Concepedia

Jochem Gokemeijer

JG

14

Publications

955

Citations

13

H-Index

1998

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Amgen (United States)

EpiVax (United States)

Jochem Gokemeijer is an author at Bristol-Myers Squibb (United States) specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1998–2023

14

Publications

14

Synthesis and Biologic Evaluation of a Novel <sup>18</sup>F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression

David J. Donnelly, R. Adam Smith, Paul E. Morin et al. · Journal of Nuclear Medicine · 2017 · 190 citations · Full text

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Vibha Jawa, Frances Terry, Jochem Gokemeijer et al. · Frontiers in Immunology · 2020 · 129 citations · Full text

Antagonists to Human and Mouse Vascular Endothelial Growth Factor Receptor 2 Generated by Directed Protein Evolution In Vitro

E. V. Getmanova, Yan Chen, Laird Bloom et al. · Chemistry & Biology · 2006 · 96 citations

, , +9

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Anthony W. Tolcher, Christopher J. Sweeney, K. Papadopoulos et al. · Clinical Cancer Research · 2011 · 85 citations

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two

Matthew H. Parker, Y. Chen, Francis T. Danehy et al. · Protein Engineering Design and Selection · 2005 · 80 citations

, , +16

Rows per page

1–5 of 14